
-
Russian strikes kill three across Ukraine
-
Robertson relieved as All Blacks survive fierce France challenge
-
Syria forces deploy in Druze heartland after US brokers deal with Israel
-
Gaza civil defence says Israeli attacks kill 26 near two aid centres
-
Bagnaia takes Czech MotoGP pole as Marquez crashes
-
DR Congo, M23 armed group sign ceasefire deal
-
All Blacks survive fierce France challenge to win third Test 29-19
-
All Blacks survive France challenge to win third Test 29-19
-
Migrants freed from El Salvador reach Venezuela in US prisoner deal
-
South Korea's ex-president indicted for abuse of power
-
Aloha, Bavaria! Munich surfers riding wild river wave again
-
'Clumsy' Japanese PM Ishiba's future in the balance
-
West Bank 'plane chalet' helps aviation dreams take off
-
US announces Syria-Israel truce as new clashes rock Druze heartland
-
Spain's Bonmati feeling '100 percent' after reaching Euros semis
-
US environment agency axes nearly a quarter of workforce
-
Pacquiao, Barrios make weights for Vegas showdown
-
Spain see off spirited Swiss to reach Euro 2025 semi-finals
-
Lowry accepted 2-shot British Open penalty over fear of 'cheat' backlash
-
Moldova ex-minister charged in Interpol corruption case
-
Canada wildfires burn area the size of Croatia
-
Dubois says victory over Usyk would put him among boxing greats
-
Fitzpatrick happy for 'Tiger-like' Scheffler to assume British Open pressure
-
Venezuela receives 7 kids left behind in US after parents deported
-
Argentines commemorate Jewish center bombing, demand justice
-
Frank aims to take Tottenham to 'new heights'
-
'Mass grave': Medics appeal for aid at last working hospital in Syria's Sweida
-
Over 11 mn refugees risk losing aid because of funding cuts: UN
-
Hojgaard twins hoping for British Open showdown
-
Usyk at career heaviest for title fight with Dubois
-
Charging Scheffler closes on British Open lead
-
Brazil police raid home of Bolsonaro, accused of plotting coup
-
France museum-goer eats million-dollar banana taped to wall
-
Pogacar extends Tour de France lead with dominant time-trial win
-
Tomorrowland music festival opens with new stage after blaze
-
Arsenal seal divisive move for Chelsea winger Madueke
-
G20 nations agree central bank independence 'crucial'
-
Pogacar extends Tour de France lead with uphill time-trial win
-
'Witnesses to despair': Marseille sees poverty fuel cocaine problem
-
Stocks consolidate after bumper week buoyed by resilient US economy
-
MacIntyre 'will not back off' in bid for first major title
-
What's in the EU's two-trillion-euro budget bazooka?
-
EU, UK target Russian oil in tough new Ukraine war sanctions
-
Barca's planned Camp Nou return in August scrapped
-
McIlroy 'excited' for shot at homecoming British Open glory
-
Hunter Harman stalking second British Open crown
-
Marquez tops Czech MotoGP practice as Martin returns
-
Disinformation catalyses anti-migrant unrest in Spain
-
Ex-Brazil president Bolsonaro must wear monitoring device: Supreme Court
-
Resilient US economy spurs on stock markets

Treatment found to reduce progression of rare blood cancer by 74%
A treatment that involves genetically modifying the body's own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type of blood cancer, results showed Monday.
Ciltacabtagene autoleucel -- also known by its trade name Carvykti -- was tested in a clinical trial involving 419 patients with multiple myeloma, whose disease was not responsive to the current frontline drug lenalidomide, a chemotherapy medicine.
"Lenalidomide has become a foundation of care for people with myeloma, but as its use has expanded, so has the number of patients whose disease will no longer respond to the treatment," said oncologist Oreofe Odejide at the American Society of Clinical Oncology's annual meeting where results were presented.
Ciltacabtagene autoleucel "delivers remarkably effective outcomes compared to patients' current options" and "can be used safely earlier in the treatment phase," added Odejide, an expert who was not part of the research.
Multiple myeloma affects a type of white blood cells called plasma cells, and can cause cascading harms to the bones, kidneys, and immune health.
It affects seven people out of 100,000 every year, according to the Cleveland Clinic, with 100,000 people impacted in the United States. There is currently no cure, though progression can be stopped for a long time.
Risk increases with age, with men more likely to be affected than women, and Black people at higher risk than other races. Not everyone requires immediate treatment and the disease may be monitored if it is slow growing.
In the new clinical trial, half the patients were randomly assigned ciltacabtagene autoleucel, while the other half received a cocktail of drugs that represents the current standard of care, including chemotherapy and steroids.
"After a median follow-up of 16 months, the researchers found that ciltacabtagene autoleucel reduced the risk of disease progression by 74 percent, compared with the standard-of-care treatments," a press statement said.
Ciltacabtagene autoleucel is a type of chimeric antigen receptor (CAR) T-cell therapy, a newer form of treatment.
CAR T-cell therapy involves removing the patient's disease fighting T cells, and genetically engineering them in a lab so they have specific proteins known as receptors that, once returned to the body, will seek out and destroy cancer cells.
Nearly all the patients in both groups experienced severe to life-threatening adverse events, including infections and low blood cell counts.
Three-quarters of patients on ciltacabtagene autoleucel developed Cytokine release syndrome, in which the immune system is sent into overdrive. It can affect multiple organs and cause death.
Around five percent of patients on ciltacabtagene autoleucel developed immune effector cell-associated neurotoxicity syndrome (ICANS), which affects a person's nervous system.
Next, the researchers will continue to follow the study participants to determine long-term effects and impacts on quality of life.
The clinical trial was funded by Janssen Research & Development and Legend Biotech USA.
M.Fischer--AMWN